<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01718366</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-EXVD-AZA-2011-005623-41</org_study_id>
    <nct_id>NCT01718366</nct_id>
  </id_info>
  <brief_title>A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS</brief_title>
  <acronym>GFM-EXVD-AZA</acronym>
  <official_title>Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determinate safety and response rate of the association Deferasirox -Vitamine D - Azacitidine&#xD;
      in treatment of high risk MDS&#xD;
&#xD;
      Deferasirox Exjade:&#xD;
&#xD;
      The dose of Deferasirox will be assigned according to the ferritin level. Dose escalation is&#xD;
      scheduled during the phase I, with 5 additional patients per group.&#xD;
&#xD;
      The maximal tolerated dose of Deferasirox will be required for the phase II of the study.&#xD;
&#xD;
      The first dose will be assigned according to the ferritin level of the patient at time of&#xD;
      inclusion:&#xD;
&#xD;
      5 mg/kg/d if the ferritin is &gt;300ng/ml and &lt; 1000ng/ml in Group 1 10 mg/kg/d if the ferritin&#xD;
      is ≥1000ng/ml) in Group 2&#xD;
&#xD;
      Group 1 : Ferritin 300 to 1000ng /ml:&#xD;
&#xD;
        -  cohort 1 : 5 mg/kg/d&#xD;
&#xD;
        -  cohort 2 : 10mg/kg/d&#xD;
&#xD;
        -  cohort 3 : 15 mg/kg/d&#xD;
&#xD;
      Group 2 : Ferritin &gt; 1000ng /ml:&#xD;
&#xD;
        -  cohort 1 : 10 mg/kg/d&#xD;
&#xD;
        -  cohort 2 : 15mg/kg/d&#xD;
&#xD;
        -  cohort 3 : 20 mg/kg/d&#xD;
&#xD;
           5 patients will be treated by cohort. In absence of toxicity (extra-hematological&#xD;
           toxicity grade 3 or 4 or hematological grade 4), 5 additional patients will be included&#xD;
           in the next cohort.&#xD;
&#xD;
      Deferasirox will be administrated once daily during all the study period. Uvedose will be&#xD;
      administrated once weekly during all the study period (100.000 UI P.O).&#xD;
&#xD;
      Azacitidine will be administrated sc at 75 mg/m²/d, during 7 days, J1 to J7 of each&#xD;
      cycles(One cycle is 28 days)&#xD;
&#xD;
      During phase I and II, Deferasirox will always be associated with Vitamin D and Azacitidine&#xD;
&#xD;
      Patients will be received 6 cycles of treatment (except if progression, unacceptable toxicity&#xD;
      or withdrawn of patients occured) After 3 and 6 cycles, an evaluation will be done to&#xD;
      evaluate the efficacy of the treatment.&#xD;
&#xD;
      No dose modification of deferasirox will be done after 3 cycles of treatment except in case&#xD;
      of progression). After 6 cycles, patients with CR, PR, marrow CR or HI will be treated with&#xD;
      the same dose of Deferasirox until progression .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deferasirox will be administrated once daily in the morning on an empty stomach, 30 minutes&#xD;
      before meal.&#xD;
&#xD;
      Deferasirox will be stopped if the ferritin level is under 100 ng/ml,and could be restarted&#xD;
      is the ferritin level increase to 200 ng/ml&#xD;
&#xD;
      Uvedose dose could be adjusted according to the phosphocalcic metabolism parameters and the&#xD;
      plasma Vitamin D3 level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximal tolerated dose(MTD</measure>
    <time_frame>6 month of treatment</time_frame>
    <description>patient will be evaluable after at least one cycle. Treatment will be administrated during 6 month and responders will be treated until progression or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>ferritin level &gt;300ng/ml and &lt; 1000ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be included in 2 groups according to the ferritin level at time of inclusion.&#xD;
Patients with the ferritin level &gt;300ng/ml and &lt; 1000ng/ml, will be included in Group 1.&#xD;
Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)&#xD;
5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ferritin level &gt; 1000ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be included in 2 groups according to the ferritin level at time of inclusion.&#xD;
Patients with the ferritin level &gt; 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)&#xD;
5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox, Vitamin D and Azacitidine</intervention_name>
    <description>association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)</description>
    <arm_group_label>ferritin level &gt; 1000ng/ml</arm_group_label>
    <arm_group_label>ferritin level &gt;300ng/ml and &lt; 1000ng/ml</arm_group_label>
    <other_name>Exjade</other_name>
    <other_name>VitaminD</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High risk MDS, according to OMS classification&#xD;
&#xD;
          -  High risk CMML (WBC &lt; 13 G/L)&#xD;
&#xD;
          -  AREBT of the FAB classification with less than 30% of blastes&#xD;
&#xD;
          -  IPSS&gt;=1.5 (int-2 and high risk)&#xD;
&#xD;
          -  Age &gt;=18y&#xD;
&#xD;
          -  Performance status&lt;=2 (ECOG)&#xD;
&#xD;
          -  Bilirubin and transaminase &lt; 1.5 x ULN&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
          -  Patient not eligible for Allogeneic stem cell transplant&#xD;
&#xD;
          -  Male and female patients must use an effective contraceptive method during the study&#xD;
             and for a minimum of 3 months after study treatment.&#xD;
&#xD;
          -  Agree the need for the use of a condom if engaged in sexual activity with a pregnant&#xD;
             woman or a woman of childbearing potential. during the entire period of treatment,&#xD;
             even if disruption of treatment and during 3 months after end of treatment&#xD;
&#xD;
          -  Male patient: Agree not to conceive during treatment and study drug therapy (including&#xD;
             doses interruptions) and for 3 months after the end of the study drug therapy&#xD;
&#xD;
          -  Agree not to donate semen during study drug therapy and for one week after end of&#xD;
             study drug therapy.&#xD;
&#xD;
          -  Agree to learn about the procedures for preservation of sperm,before starting&#xD;
             treatment&#xD;
&#xD;
          -  Patient be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection or uncontrolled disease&#xD;
&#xD;
          -  Use of cytotoxic chemotherapeutic agents or experimental agents(agents that are not&#xD;
             commercially available) for the treatment of MDS within 28 days. In case of used of&#xD;
             cytotoxic chemotherapeutic agents or hypomethylating agent a wash out of 3 mont is&#xD;
             required.&#xD;
&#xD;
          -  Active Cancer or Cancer within one year before inclusion&#xD;
&#xD;
          -  Previous calcic urinary lithiasis&#xD;
&#xD;
          -  Previous hyperparathyroid primitive disease or uncontrolled&#xD;
&#xD;
          -  Hypercalcemia, hyperphosphoremia, hypervitaminosis D&#xD;
&#xD;
          -  Patient already include in another experimental study&#xD;
&#xD;
          -  Active infection by HIV, hepatite B or C&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Patient not able (medical/psychiatric) to understand and sign the written consent&#xD;
&#xD;
          -  Patients with a ferritin level less than 300ng/ml&#xD;
&#xD;
          -  Patient eligible for an Allogeneic stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital (Paris)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fenaux, MD</last_name>
    <role>Study Director</role>
    <affiliation>Saint Louis Hospital (Paris)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Suarez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Necker Hospital (Paris)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GENT</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Boulogne sur Mer</name>
      <address>
        <city>Boulogne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Le Mans</name>
      <address>
        <city>Le MANS</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2012</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

